Enveda has appointed Christopher K. Porter as Senior Vice President of Clinical Operations, adding an experienced drug-development executive as the privately held biotechnology company advances multiple programs into the clinic. Porter joins Enveda as it expands its clinical pipeline and builds internal infrastructure to manage late-stage development. The company, founded in 2019, uses artificial intelligence to identify potential drug candidates derived from compounds found in nature. Di...